<DOC>
	<DOCNO>NCT00037531</DOCNO>
	<brief_summary>To evaluate safety long-term administration sirolimus oral solution 5 additional year , tablet formulation commercially available ( whichever occurs first ) solid organ transplant recipient currently receive sirolimus complete clinical trial sirolimus ( without cyclosporine ( CsA ) . To evaluate pharmacokinetics safety long-term administration sirolimus tablet administer 5 year , tablet formulation commercially available solid organ transplant recipient currently receive sirolimus complete clinical trial sirolimus ( without CsA ) currently enrol protocol 0468E1-306-US .</brief_summary>
	<brief_title>Study Evaluating Sirolimus ( Rapamuneâ„¢ ) Solid Organ Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Completion sirolimus/blinded therapy solid organ clinical trial ( without CsA ) satisfactory compliance adequate safety profile . Women childbearing potential negative pregnancy test enrollment study agree practice either hormonal barrier method birth control throughout treatment period 3 month follow discontinuation sirolimus may enrol study . Signed date informed consent Unstable disease state , opinion investigator would present risk patient . Known hypersensitivity macrolide antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Transplant</keyword>
	<keyword>Kidney</keyword>
</DOC>